Keyphrases
Crohn's Disease
70%
Inflammatory Bowel Disease
68%
Pediatric Patients
51%
Pediatric Inflammatory Bowel Disease
51%
Pediatric Crohn's Disease
37%
Pediatric
29%
Granulocyte Colony-stimulating Factor (G-CSF)
29%
Infliximab
26%
Hepatocytes
25%
Hepatocyte Apoptosis
23%
Ulcerative Colitis
19%
Crohn's Colitis
19%
Apoptosis
18%
Nuclear factor-κB
18%
Corticosteroids
15%
Remission
14%
Budesonide
14%
Hepatocyte Proliferation
13%
Non-steroidal Anti-inflammatory Drugs (NSAIDs)
13%
NOD2
12%
Ileitis
12%
Autoantibodies
11%
Gene-deficient Mice
11%
Pragmatic Trial
11%
Protein Expression
11%
Improved Outcomes
11%
Monotherapy
10%
Tumor Necrosis Factor-α
10%
Pragmatic Clinical Trial
10%
Ileal Crohn's Disease
10%
Obstructive Jaundice
9%
Low-dose Methotrexate
9%
Statural Growth
9%
Expected Growth
9%
Growth Plate Closure
9%
Comparative Effectiveness
9%
Non-alcoholic Fatty Liver Disease (NAFLD)
9%
Learning Health System
9%
Anti-tumor Necrosis Factor (anti-TNF)
9%
Monogenic
9%
Clinical Endpoints
9%
Healthcare Research
9%
Systemic Corticosteroids
9%
Older Adults
9%
Colitis
9%
Histoplasmosis
9%
Older Adolescents
9%
Computed Tomography
9%
Heterozygous Variant
9%
GM-CSF Autoantibody
9%
Medicine and Dentistry
Pediatrics
100%
Inflammatory Bowel Disease
81%
Crohn's Disease
51%
Pediatrics Patient
49%
Patient with Crohn's Disease
32%
Drug Therapy
29%
Biological Product
29%
Quality Improvement
20%
Hepatocyte
19%
Programmed Cell Death
19%
Patient with Inflammatory Bowel Disease
15%
Therapeutic Drug Monitoring
14%
Infliximab
12%
Tumor Necrosis Factor
12%
Colitis
11%
Ulcerative Colitis
11%
Case-Control Study
9%
Electronic Health Record
9%
Nonalcoholic Fatty Liver
9%
Patient-Reported Outcome
9%
Outcome Assessment
9%
Immunosuppressive Drug
9%
Health System
9%
Clinical Trial
9%
Epiphyseal Plate
9%
Juvenile Idiopathic Arthritis
9%
Budesonide
9%
Fibrinogen
9%
Emergency Department
9%
Closed Head Injury
9%
Computer Assisted Tomography
9%
Cell Cycle
9%
Transforming Growth Factor
9%
Mating Hormone Alpha Factor
9%
Gut
9%
Infusion
9%
Protein Binding
9%
Necrosis
9%
Lymphocyte
9%
Granulocyte Macrophage Colony Stimulating Factor
9%
Histoplasmosis
9%
Medical Record
9%
Immunoglobulin Enhancer Binding Protein
8%
Immunomodulating Agent
7%
Monoclonal Antibody
7%
Drug Megadose
7%
Biological Therapy
7%
Prevalence
6%
S Phase
5%
Infection
5%
Pharmacology, Toxicology and Pharmaceutical Science
Crohn's Disease
99%
Inflammatory Bowel Disease
51%
Tumor Necrosis Factor
34%
Biological Product
30%
Ulcerative Colitis
25%
Infliximab
21%
Remission
21%
Budesonide
19%
Granulocyte Macrophage Colony Stimulating Factor
19%
Immunoglobulin Enhancer Binding Protein
18%
Therapeutic Drug Monitoring
14%
Methotrexate
12%
Ileitis
11%
Mouse
11%
Monotherapy
10%
Non-Steroidal Anti-Inflammatory Drug
10%
Autoantibodies
10%
Injury
10%
Obstructive Jaundice
9%
Adalimumab
9%
Clinical Trial
9%
Necrosis
9%
Mating Hormone Alpha Factor
9%
Smad Protein
9%
Caspase
9%
Transforming Growth Factor
9%
Fibrinogen
9%
Mercaptopurine
9%
Binding Protein
9%
Histoplasmosis
9%
Disease Activity
9%
Combination Therapy
8%
Disease
8%
Immunomodulating Agent
7%
Monoclonal Antibody
7%
Malignant Transformation
7%
Placebo
6%
Symptom
5%
Cholestasis
5%
Luciferase
5%
Adenoviridae
5%
Infection
5%
